This section contains references to information on clinical trials related to carcinoid cancer and neuroendocrine tumors. This section may not represent an inclusive list of all clinical trials that are in process or being planned worldwide.
Clinical Trials.gov (Specifically for carcinoid/NETs)
The U.S. National Institutes of Health, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members and members of the public current information about clinical research studies.
For additional clinical trials contact the NCI's Cancer Information service at
800-422-6237
NEW CLINICAL TRIAL has just opened up for neuroendocrine patients:
Location and Contact Information Please refer to this study by ClinicalTrials.gov identifier NCT00501540
United States, Wisconsin
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, 53792, United States;
Recruiting
Cancer Connect 800-622-8922
Kelly Richie 608-263-7283
Kyle D Holen, MD, Principal Investigator
Study chairs or principal investigators
Kyle D Holen, MD, Principal Investigator, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Herbert Chen, MD, Study Chair, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
For more information CLICK HERE
Now recruiting University of California, San Francisco (UCSF) Comprehensive Cancer Center - Clinical Trial
Chemotherapy drugs like 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) work in different ways to cause tumor cells to stop growing or die. Bevacizumab is a monoclonal antibody that may inhibit cancer growth by blocking blood flow to tumors. Adding bevacizumab to combination chemotherapy may be a better way to block tumor growth than giving either type of therapy alone. The FOLFOX plus bevacizumab combination is being studied in patients with neuroendocrine tumors because FOLFOX appears to inhibit the growth of a variety of different tumor types but has not yet been tested in this disease. In addition, neuroendocrine tumors appear to depend on blood vessels for growth suggesting that they may respond to a treatment like bevacizumab. This clinical trial is for patients who have not responded to other treatments to see if the FOLFOX/bevacizumab combination is safe and if it can inhibit the growth of metastatic neuroendocrine tumors.
LOCATION AND CONTACT INFORMATION
Mary O’Rourke, R.N.
Clinical Trials Recruitment Nurse
UCSF Comprehensive Cancer Center
Clinical Research Support Services
1600 Divisadero Street
San Francisco, CA 94115
Tel: (415) 353-9612
Fax: (415) 353-9738
Email: morourke@cc.ucsf.edu
Please visit